General
Preferred name
IMIQUIMOD
Synonyms
IMIQUIMOD HYDROCHLORIDE ()
R 837 hydrochloride ()
Imiquimod (Aldara) ()
Aldara ()
1H-Imidazo[4,5-c]quinolin-4-amine, 1-(2-methylpropyl)- ()
Imiquimod (hydrochloride) ()
Imiquimod (maleate) ()
R 837 ()
R 837 (hydrochloride) ()
R 837 maleate ()
Imiquimod (R-837) ()
Aldara,R-837, S-26308 ()
Imiquimod maleate ()
Zyclara ()
NSC-759651 ()
NSC-369100 ()
S26308 ()
Tmx-101 ()
S-26308 ()
R-837 ()
Imiquimod-d9 ()
P&D ID
PD002592
CAS
99011-02-6
9050-31-1
99011-78-6
896106-16-4
2712126-48-0
Tags
natural product
drug
available
Approved by
EMA
FDA
First approval
1997
Drug Status
investigational
approved
withdrawn
Drug indication
Immunomodulator
Skin cancer
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Imiquimod is a TLR7 agonist acting as an immunomodulator. (GtoPdb)
DESCRIPTION Selective ERK inhibitor (Tocris Bioactive Compound Library)
DESCRIPTION Caspase 3 activator (LOPAC library)
DESCRIPTION Imiquimod hydrochloride is an immune response modifier. It acts as a toll-like receptor 7 agonist. It is commonly used topically to treat warts on the skin of the genital and anal areas. It is also used to treat certain diseases of the skin, including skin cancers, such as basal cell carcinoma, Bowen's disease, superficial squamous cell carcinoma, some superficial malignant melanomas, and actinic keratosis. It can lead to the activation of Langerhans cells, which subsequently migrate to local lymph nodes to activate the adaptive immune system when applied to skin. (BOC Sciences Bioactive Compounds)
DESCRIPTION Imiquimod maleate is an immune response modifier. It acts as a toll-like receptor 7 agonist. It is commonly used topically to treat warts on the skin of the genital and anal areas. It is also used to treat certain diseases of the skin, including skin cancers, such as basal cell carcinoma, Bowen's disease, superficial squamous cell carcinoma, some superficial malignant melanomas, and actinic keratosis. It can lead to the activation of Langerhans cells, which subsequently migrate to local lymph nodes to activate the adaptive immune system when applied to skin. (BOC Sciences Bioactive Compounds)
Cell lines
2
Organisms
1
Compound Sets
33
AdooQ Bioactive Compound Library
A10469
Axon Medchem Screening Library
3107
BOC Sciences Bioactive Compounds
imiquimod-hydrochloride-cas-99011-78-6-item-474934
imiquimod-maleate-cas-896106-16-4-item-474895
Cayman Chemical Bioactives
14956
26424
ChEMBL Approved Drugs
CHEMBL1282
ChEMBL Drugs
CHEMBL1282
Concise Guide to Pharmacology 2017/18
5003
Concise Guide to Pharmacology 2019/20
5003
Concise Guide to Pharmacology 2021/22
5003
Concise Guide to Pharmacology 2023/24
5003
Drug Repurposing Hub
DrugBank
DB00724
DrugBank Approved Drugs
DB00724
DrugCentral
1429
DrugCentral Approved Drugs
1429
DrugMAP
DM1TMA3
DrugMAP Approved Drugs
DM1TMA3
DrugMatrix
Enamine BioReference Compounds
Guide to Pharmacology
5003
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1282
MedChem Express Bioactive Compound Library
HY-B0180A
HY-B0180
HY-B0180B
NCATS Inxight Approved Drugs
P1QW714R7M
NIH Approved Oncology Drugs
48426262
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Imiquimod
The Spectrum Collection
Tocris Bioactive Compound Library
3700
Withdrawn 2.0
EMA21
External IDs
55
Properties
(calculated by RDKit )
Molecular Weight
240.14
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
2
Ring Count
3
Aromatic Ring Count
3
cLogP
2.82
TPSA
56.73
Fraction CSP3
0.29
Chiral centers
0.0
Largest ring
6.0
QED
0.75
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
Casp3
Primary Target
Toll-like Receptors
MOA
Agonist
TLR7 Receptor Agonists
Interferon Inducers
interferon inducer, toll-like receptor agonist
Member status
member
Indication
actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)
Disease Area
dermatology, infectious disease, oncology
Target
TLR7, TLR8
TLR7/TLR8 agonist
HSV
SARS-CoV
Toll-like Receptor (TLR)
Immunology & Inflammation related
ATC
D06BB10
L03AX
Therapeutic Class
Antiviral Agents
Pathway
Anti-infection
Autophagy
Immunology/Inflammation
Solubility
10 mM in DMSO
Source data